LGLi-Ying Gu

Li-Ying Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Li-Ying Gu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • An-Yue Wu

    Department of Obstetrics and Gynaecology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, China

    2 shared publications
  • Lihua Qiu

    Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    2 shared publications
  • Wei Cang

    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China

    2 shared publications
  • Wen-Jing Wang

    Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, China

    2 shared publications
  • Dong Li

    Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, 200127, China; Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, China

    1 shared publication
  • Fang Ji

    Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, 200127, China; Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, China

    1 shared publication

Latest Publications

  • Suppressive effect of microRNA-449a on the NDRG1/PTEN/AKT axis regulates endometrial cancer growth and metastasis

    by An-Yue Wu, Yuan Hu, Wei Cang, Dong Li, Wen-Jing Wang, Qi Tian, Li-Ying Gu, Ning Zhang, Fang Ji, Li-Hua Qiu


  • Open Access

    Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation

    by An-Yue Wu, Li-Ying Gu, Wei Cang, Meng-Xing Cheng, Wen-Jing Wang, Wen Di, Lei Huang, Li-Hua Qiu

    High-grade serous ovarian cancer (HGSOC) is the most lethal of all gynecological malignancies. Patients often suffer from chemoresistance. Several studies have reported that Fn14 could regulate migration, invasion, and angiogenesis in cancer cells. However, its functional role in chemoresistance of HGSOC is still unknown. The expression of Fn14 in tissue specimens was detected by IHC. CCK-8 assay was performed to determine changes in cell viability. Apoptosis was measured by flow cytometry. The potential molecular mechanism of Fn14-regulated cisplatin resistance in HGSOC was investigated using qRT-PCR, western blotting, and Co-IP assays. The role of Fn14 in HGSOC was also investigated in a xenograft mouse model. In this study, we found that Fn14 was significantly downregulated in patients with cisplatin resistance. Patients with low Fn14 expression were associated with shorter progression-free survival and overall survival. Overexpression of Fn14 suppressed cisplatin resistance in OVCAR-3 cells, whereas knockdown of Fn14 did not affect cisplatin resistance in SKOV-3 cells. Interestingly, Fn14 could exert anti-chemoresistance effect only in OVCAR-3 cells harboring a p53-R248Q mutation, but not in SKOV-3 cells with a p53-null mutation. We isolated and identified primary cells from two patients with the p53-R248Q mutation from HGSOC patients and the anti-chemoresistance effect of Fn14 was observed in both primary cells. Mechanistic studies demonstrated that overexpression of Fn14 could reduce the formation of a Mdm2-p53-R248Q-Hsp90 complex by downregulating Hsp90 expression, indicating that degradation of p53-R248Q was accelerated via Mdm2-mediated ubiquitin-proteasomal pathway. Our findings demonstrate for the first time that Fn14 overcomes cisplatin resistance through modulation of the degradation of p53-R248Q and restoration of Fn14 expression might be a novel strategy for the treatment of HGSOC.